 TORONTO, July 20, 2021 PRNewswire - Braxia Scientific Corp. Braxia, or the Company, CSE: BRAX OTC: BRAXF FWB: 496, a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce that it has established direct billing practices with health insurance provider Medavie Blue Cross for qualifying Canadian military veterans. The foregoing development will allow for 100 coverage of oral, nasal spray and intravenous ketamine treatments, plus travel costs, delivered at the Canadian Rapid Treatment Centre of Excellence CRTCE, a wholly owned subsidiary of Braxia. 